Your Messages Inbox
Your Article Summary
See Latest ArticlesAVI BioPharma Receives Key Patents for Drug Candidate AVI-6002 Targeting Ebola Zaire Virus Protein VP35
AVI BioPharma, 04/29/09
AVI BioPharma, Inc. , a developer of RNA-based drugs, today announced issuance of the second of two key U.S. patents covering the Company's candidate drug for the treatment of Ebola Zaire infection. The patents titled "Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection" , cover composition and methods to target the Ebola virus VP35 protein with a range of PMOplus compounds. The patents have an expiration date of Oct. 2025.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
Article Search
Sponsor